bmte: AN I REGION MUTANT Materials and Methods
Mice. The mice used are listed in the Tables. 3 The inbred strains were maintained by strict brother X sister breeding in Melbourne, Australia. The mutant, produced as C57BL/6-H-2 bin12
(henceforth referred to as bm x2) was freighted to Melbourne from the Harvard Medical School and Warren Radiation Center, New England Deaconess Hospital, Boston, Mass. The bm 12 mutant arose in a (C57BL/6Kh × BALB/cKh)F1 and the mutation was shown to be in the H-2 b haplotype of C57BL/6. The original Fa hybrid mouse bearing the mutation was backcrossed and made congenic with C57BL/6Kh (12) .
Serological Studies. Antisera were produced as previously described (3) . Some H-2 and Ia antisera were obtained from Dr. J. Ray of the Transplantation Immunology Branch, National Institute of Allergy and Infectious Diseases, Bethesda, Md. and are described in the Institute's Catalog of Mouse Alloantisera. Cytotoxicity, and absorption testing using cytotoxicity, were performed as previously described (5) . For these tests, selected rabbit sera were used as a source of complement. Rosetting assays for direct testing and absorption were also performed, using sheep anti-mouse IgG coupled to sheep erythrocytes with chromic chloride (11) . The spleen cells had their surface Ig removed by capping before use (11) . All sera used and their cytotoxicity and rosetting titers are shown in the Tables. Erythrocytes were also tested by the hemagglutination method (3, 5) .
Skin Grafting and Complementation Studies.
Skin grafts were performed as described elsewhere (3, 11) using either tail skin to dorsum (Melbourne) or tail skin to tail (Boston). To genetically map the site of the mutation, the standard gene-complementation test was performed (2) . This involved grafting C57BL/6Kh skin to F1 recipients formed by mating a C57BL/10 recombinant strain (differing from the H-2 b haplotype at known loci) with the bm 12 mutant. In these circumstances, graft rejection indicates a failure of the recombinant strain to complement the bm 12 mutant for a C57BL/6 graft, and so the recombinant and mutant strain both lack the necessary H-2 b gene required for complementation. Graft acceptance indicates that the recombinant strain carries the appropriate H-2 b gene so that (recombinant × bm12)Fi is identical to the parental C57BL/6 strain.
Mixed Lymphocyte Reaction (MLR)
CELL PREI~ARATXON. Spleen and lymph node cells were teased in RPMI-1640 medium (Commonwealth Serum Laboratories, Melbourne, Australia) supplemented with 2.5% human serum, 20 mM Hepes buffer, 100 U/ml penicillin, 100 #g/ml streptomycin, 2 mM/L-glutamine and 5 × 10 -~ M 2-mercaptoethanol. Cell suspensions were centrifuged at 1,000 rpm for 5 rain and washed twice. CULTURE CONDmONS. Responder lymph node cells were adjusted to 1 X 10 6 viable cells/ ml. Spleen cells at 5 × 106/ml were treated with mitomycin C (Sigma Chemical Co., St. Louis, Mo.) at 25/~g/ml for 25 min at 37°C, washed three times and finally adjusted to 2 × 106/ml and used as stimulating cells in the MLR. Responder cells (0.1 ml) were cultured with 0.1 ml of stimulator cells in U-bottom Cooke microtiter plates (Cooke Engineering Co., Alexandria, Va.). Cultures were set up in quadruplicate incubated at 37°C in a humidified atmosphere of 10% CO2/90% air for 4 d, labeled with [aH]thymidine (2/zCi/well; 5 Ci/mmol sp act) and incubated for a further 20-24 h. Cells were harvested, using a Skatron multiple cell harvester (Flow Laboratories, Sydney, Australia) on to glass fiber filters (Titertek filter mats, catalogue No. 77-300-06, Flow Laboratories) which were then dried and placed into vials containing 10 ml of scintillation fluid [1.1 g POPOP, (Kochlight Laboratories, Buckinghamshire, England) 5 g PPO (Packard, Melbourne, Australia) per I of toluene].
Results
Description ofbm 12 Mutant. The bm lz mutant was first detected as a gain and loss mutation in grafting between (C57BL/6 × BALB/c)F1 mice. The mutation was 3 The most recent listing of all available mutants, their haplotypes, properties and origin will be found in (a) Kohn, H. I.,J. Klein shown to be in the H-2 b haplotype of C57BL/6 (see below) and the strain was then made homozygous on a C57BL/6Kh background. Both C57BL/6 and bm a2 reject each other's skin grafts in 14-16 d (Table I) indicating that the mutation is of both the gain and loss type, and further, the mutation has induced histogenic changes of similar strength to the strongest responses found with the H-2K b mutants (4).
Mapping the bm tx Mutation to the IA subregion of C57BL/6.
The results of the original studies (12) and of the complementation studies indicate several points of importance (Table II) . Firstly, the finding that the (B6.C-H-2 d X bm12)F1 hybrid rejects C57BL/ 6 grafts indicates that the mutation is not in the H-2 d haplotype of BALB/c but has occurred in the H-2 b haplotype, particularly as the original Fa mutant rejected C57BL/6 and accepted BALB/c grafts. Secondly, crosses with other H-2 b mutants indicate that the bm 12 mutant occurred at a third mutational site within the H-2 b haplotype. This was shown by the cross with bm 13 which we have mapped to H-2D b (G. M. Morgan, H. Dellos, I. F. C. McKenzie, D. W. Bailey, and R. W. Melvold. Studies of the bm la and bm 14 mutants of C57BL/6. Manuscript in preparation.). The ability of bm 13 to complement the bm 12 mutant indicates that the bm 12 mutation occurred at a site other than H-2D b locus. Crosses with four different H-2K b mutants (bm 1, bm 5, bm 6, and bmS), which are all mutant alleles at the one (H-2K b) mutational locus, also complemented the mutant bm lz strain for a C57BL/6 graft. These results demonstrate that this second mutational site, probably H-2K b itself, is also not the site of the bm a2 mutation, which must therefore have occurred at a third H-2 b mutational site, distinct from both H-2K b and H-2D b. Complementation occurred in the cross with B10.A(5R) which localized the mutation either to K b, IA b or, IB b subregion. Finally, complementation studies in two other crosses with B10.A(4R) or D2.GD excluded the IB b subregion. The bm 12 mutation therefore occurred in either the IA ~ subregion or in the H-2K b region, but at a different site to the H-2K b locus. (This was our first, but incorrect conclusion. 2) However, from the serological evidence it is extremely likely that the mutation occurred in the IA subregion.
Serological Studies Comparing C57BL/6 and bm le with H-2 Alloantisera. The sera used and the results obtained are shown in Table III . When tested directly using cytotoxicity with rabbit serum as a source of complement, all sera, with the exception of an H-2.33 antiserum gave identical or similar results with the C57BL/6Kh parental strain and the bm 12 mutant, i.e., there was no difference in the reaction of the two strains with sera detecting the H-2.2, 5, 27, 28, 29, 35, and 36 specificities (Table III) . With the H-2.33 antisera, several different patterns of reaction were observed with the two different antisera (Table III and Fig. 1 ). The D33 and AS924 sera both gave 
* The strains listed in the column were crossed with bm 12 and the FI hybrid grafted with C57BL/6Kh skin from a donor of the same sex. Groups of 6-I0 mice were used. Grafts either did not reject in periods of observation >60 d or were rejected in 12-18 d. Mutational site.
similar direct reaction patterns and titers. These two sera, made as (B10.D2 × A)F1 anti-B10.A(5R) could potentially contain anti-Ia.9 and 20 antibodies. The titer of bm TM with these sera was lower than found in C57BL/6 although the shape of the titration curve did not differ in the two strains. Furthermore, AS924 absorbed with A.TH, to remove the Ia.9 antibody, gave similar titers on both C57BL/6 and bm 12.
Clearly the H-2.33 specificity is represented equally on both strains. However two other sera, AS 1117 and a similar serum (kindly provided by Dr. C. S. David, Mayo Clinic, Rochester, Minn.) and made as (B10.A × A)F1 anti-B10.A(5R) gave a different reaction (Fig. 1) . These sera could and do contain anti-Ia antibodies. On testing the parental C57BL/6 strain, there were two plateaus of reaction: (a) >90% lysis indicative of lysis resulting from H-2.38 antibodies, and (b) ~60% lysis, presumably a result of the Ia antibodies. When these sera were tested on the bm 12 mutant, only one plateau with >90% lysis was observed and the second Ia plateau was absent (Fig. 1 ). This finding suggested that the bm 12 mutant was not reacting with the antiIa component in these sera and therefore might have altered Ia specificities, the alteration being produced by the mutation. Further studies with the H-2 antisera involved testing by absorption using the same sera. Except for the H-2.33 sera, identical absorption patterns were obtained with all the H-2 antisera. Two of these are shown in Fig. 2 a, b; H-2.5, a public H-2 b specificity, and the serum D28 contains antibodies to the H-2.28 family of specificities. There is obviously no difference in the absorption capacity of either strain for serum D28 (Fig. 2 a) or for D5 (Fig. 2 b) and identical absorption of C57BL/6 and bm 12 were apparent for the other H-2 specificities (data not shown). By contrast, the two different anti-H-2.33 sera gave different absorption patterns (Fig. 3a, b) . One serum, AS924, demonstrated that bm lz had slightly less absorptive capacity when compared with C57BL/6 ( Fig. 3 a) . The other serum (from C. S. David) gave very different results in that C57BL/6 could absorb Fig. 4a ), but this was not so apparent with the more sensitive rosetting procedure (Table IV, Fig. 4 b, i.e., titers of 1/1,500 vs. 1/3,000). A similar result was obtained using AS760 (B10.HTT X A.SW)Fa anti-A.TL. The known specificities in these sera were then examined individually.
la.3. The Ia. Ia. 15. The Ia. 15 specificity was tested directly with AS767 where the bm 12 mutant was nonreactive by cytotoxicity and only weakly reactive by rosetting (Table IV, Fig.  6a ). These reactions were also examined by absorption (Fig. 6b ) and this demon- (21) . $ All of the sera listed react with the donor; the specificities in this column could potentially be present; not all are present; e.g., AS538 contains no la. 15 reactivity as C57BL/6 is negative. § The Ia.6 specificity is difficult to produce and the sera usually contain only la.7, 22. This serum does contain an la.6 antibody for, after absorption with CBA, it is B 10.D2(+).
strated that bm 12 carries ~2-I/64 the amount of Ia.15 carried by C57BL/6. This specificity was also examined by using the A.TH anti-A.TL serum with D2.GD target cells (Ia.3-15 +) so that absorption resulting from the Ia. 15 specificity only is examined (Fig. 6 c) . It was found that bm 12 has a very low absorptive capacity (1/~th) compared with C57BL/6Kh. The Ia.15 specificity is therefore present in very small amounts, and may indeed be absent. Ia.8. Testing for the Ia.8 specificity with AS742 demonstrated an extremely weak reaction with bm 12 by cytotoxicity (0-1/4 on different occasions) (Table IV, Fig. 7 a) . In addition direct testing using a monoclonal Ia.8 antibody (Table IV) , C57BL/6Kh was found to be reactive (titer 1/16), whereas bm 12 gave a barely detectable response (0--1/2 titer). (This antibody was provided by Dr. G. H/immerling, Institute for Genetics, University of Cologne, Cologne, Federal Republic of Germany; full details of these tests will be provided elsewhere.) Direct testing by rosetting indicated that bm x2 gave a greater reaction than by cytotoxicity (Fig. 7 b) . However, when testing the AS742 serum on C57BL/6 after performing quantitative absorptions with bm 12 and C57BL/6 (Fig. 7 c) , it was clear that bm 12 carried no Ia.8 specificity, especially by rosetting (Fig. 7 b) . The weak reaction of the serum directly on bm ~2, which is Ia.8-by absorption, indicates that there are other antibodies in this serum, reactive with the bm 12 mutant. This is considered further below and studies are currently in progress to define these specificities. Ia.9. The Ia.9 specificity could not be detected on the bm ~2 mutant by cytotoxicity using AS735 (Table IV) but gave a weak reaction by rosetting (Fig. 8 a) . Absorption testing indicated that the bm 12 serum carried (1/16--1/32) the amount of Ia.9 as the parental C57BL/6 strain (Fig. 8 b) . A monocloncal anti-Ia.9 antibody (obtained from Dr. G. Hiimmerling) was also nonreactive on the bm x2 mutant (Table IV) .
Ia.20. The Ia.20 specificity was tested for by using AS1117: (B10.A × A)F1 anti-B10.A(5R) absorbed with EL4 to remove H-2 antibodies. The serum could putatively contain antibodies to Ia.8, 9, 20; it was nonreactive with bm 12 but still reacted with C57BL/6 (titer 1/64) and we therefore presume that Ia.20 is also missing but we have no independent proof that the Ia.20 specificity is represented in this antisera.
The results presented in this section indicate that a dramatic alteration has occurred in the structure of the/A-coded Ia-bearing molecule in that the specificities, Ia. 
ABSORBING CELLS (X106)
FIo. 6. Testing for the Ia.15 specificity with C57BL/6 (0) and the bm TM mutant strain (×) using AS767 (Ia.15) (a, b) with C57BL/6 target cells, and ASI070 with D2.GD target cells (c). In (a), direct testing by rosetting is shown and in (b), testing is shown by absorption using the same assay system. In (c), absorption using cytotoxicity is recorded. (ll) nonabsorbed (NA) serum reaction. sought these answers by three different approaches. Firstly, C57BL/6 and bm 12 were tested with a range of antisera detecting known Ia specificities of other haplotypes, e.g., for Ia.1, 2, 4, 6, 7, 10, 11, 13, 15, 16, 17, 18, 19, and 22. All were nonreactive on both C57BL/6 and the bm 12 mutant, although not all the sera used can be guaranteed to contain all the specificities listed. However the mutation did not appear to give rise to a new specificity which had previously been described. The second approach involved absorbing sera with the bm 12 mutant and testing on C57BL/6. Although these studies are still in progress, it is clear that serum 1070 (A.TH anti-A.TL) does contain extra specificities, which can especially be detected by the rosetting procedure (Table IV; Figs. 4a, b). This was confirmed when this serum, absorbed with bm 12, still gave a substantial reaction on C57BL/6 (Table IV) . The third approach involved immunization. In several different combinations extensive immunizations were performed but no anti-Ia antibody resulted (Table V) . This result is not too surprising as it has proven difficult to produce antisera by immunizing between mutant and parental strains (5). The bm 12 Mutant has Normal B-Cell Numbers. As Ia specificities were detected only with difficulty in the bm 12 mutant, it could be considered that this mouse (which survives as a healthy strain but which breeds poorly) had low numbers of B cells--the cell bearing Ia specificities in mouse spleen. Several spleen cell suspensions were examined for the proportion of Ig + rosette-forming cells (RFC) using sheep antimouse Ig coupled to sheep erythrocytes. The results (percentage of Ig + cells) were: C57BL/6 (52-58%); bm 12 (51-56%); i.e., the bm 12 mutant has a normal content of B cells in the spleen.
MLR Studies with C57BL/6 and bm 12. The MLR data is shown in Table VI . The mutation in bm 12 has not only led to histocompatibility and serological changes in the IA subregion, but also to an alteration that leads to a reaction in the mixed lymphocyte culture. Firstly, bm 12 spleen cells are able to stimulate C57BL/6 lymph node cells (experiment 1, Table VI), the degree of stimulation being similar to those obtained when either C57BL/6 (experiment 7) or bm 12 (experiment 8) stimulate B10.A(4R) or when B10.A(4R) stimulates C57BL/6 (experiment 5). In the experiments involving B10.A(4R), there is a strong degree of stimulation as a result of lymphocyte-activating determinants (Lad) loci present in both the K and IA subregion so that the stimulation of C57BL/6 produced by bm 12 (experiment 1) is as great, or greater than that produced by a K + IA region difference. In experiment 1, C57BL/ 6 is presumably responding to the gained specificities on bm ~2, as bm TM is both a gain and loss mutation (Table I ). In the reciprocal experiment (experiment 3, Table VI), bm TM is able to respond to C57BL/6, although in this study, not as strongly as does C57BL/6 to bm 12. The presumption in this experiment is that bm 12 has lost specificities, which are present in the parent C57BL/6 and which lead to stimulation. It should be noted that B 10.A(4R) both stimulates, and responds to C57BL/6 and bm 12 in a similar manner (experiments 5-8). It is clear that the one mutational event has simultaneously effected the MLR (Lad loci) as much as the other parameters discussed above.
Discussion
The experiments reported here described the bm ~2 mutant--a spontaneous mutant occurring within the H-2 b complex of strain C57BL/6Kh. The mutation is of the gain and loss type--defined by skin grafting in that bm lz rejects parental C57BL/6 grafts (loss mutation) and C57BL/6 rejects bm 12 skin grafts (gain mutation). The mutation presumably a single gene mutation, 4 has been mapped by the standard complementation method to the K b or IA b regions of the H-2 complex (Table I) . Further complementation studies with a series ofH-2K b mutants (Table I ) have demonstrated that the mutation is not in the H-2K b locus itself, but does not exclude the mutational site being adjacent in the K region. Only studies with newer recombinant strains will solve this question. However, the mapping by complementation also includes the IA subregion and in this subregion is another histocompatibility locus, H-2IA, and it is entirely possible that the bm x2 mutation has effected this gene, particularly as there is also clear evidence for an alteration in the Ia specificities which are coded for by genes in the IA subregion. Taken together, the complementation and serological studies place the mutational site in the IA subregion. The serological studies, performed both directly and by absorption with H-2 and Ia sera, and using two different techniques (cytotoxicity and rosetting) demonstrate very clearly that the bm 12 mutant has an extensive alteration in the IA subregion Ia specificities, but not in H-2K b (or D b) specificities. The initial studies were misleading (Figs. 3 a, b) as they demonstrated an alteration in the H-2K.33 specificity. However, this antiserum also contains the Ia.9 specificity and subsequent tests revealed that H-2.K33 of bm x2 and C57BL/6 were identical, but that the bm TM lacked the Ia.9 specificity. All other direct and absorption studies with H-2 antisera to private and public H-2 b specificities also demonstrated an identity of C57BL/6 and bm lz. Although these findings with H-2 antisera do not prove that the mutation is in a site other than the H-2K b locus (because serologically detected alterations in H-2.33 in the H-2K b mutants are difficult to detect [1, 2] ), with the accompanying demonstrable alteration in the IA subregion specificities, there is compelling evidence to conclude that the mutation occurred in the IA subregion and furthermore, in the Ia-I gene which codes for the Ia specificities Ia.3, 8, 9, 15, 20. All of these specificities appeared to be altered in some way so that they are either absent, or have a reduced amount in bm 12 compared with C57BL/6. These specificities are very likely to be on the same molecule, although coprecipitation analysis with sera to all specificities has not been simultaneously performed to conclusively demonstrate this. For example, Ia.8 and 9 have been shown by coprecipitation, to be on the same molecule coded for by the IA subregion (16) . The same was shown to be true for specificities Ia. 8, 9, and 20 (17 What then of the gain mutation which leads to graft rejection of bm 12 by C57BL/ 6? We have used several approaches to study this. Firstly, antisera to almost all known Ia specificities (Table IV) were tested on C57BL/6 and bm 12. All were nonreactive by both cytotoxicity and rosetting, so that alteration to another known specificity, or mutation of the la-1 b allele to another known allele has not occurred. Rather, the mutation had led to the appearance of a new (Ia-I bin) allele at this locus. The transition from one known allele to another has not been discovered for the 11-2 mutants, but there is recent and conflicting evidence that such changes can occur in tumours (19) and tumour cell variants (19, 20) . The second approach to detect the gained specificities was standard: immunizations were performed between bm 12, C57BL/6, or Fx hybrids (Table V) to attempt to produce an anti-bm lz cytotoxic or rosetting antibody. All such attempts have failed thus far but this is the usual finding (1) and we are continuing different approaches to attempt to produce specific antibm 12 Ia antibodies. The immunization in the reverse direction such as bm 12 anti-C57BL/6 also failed to produce an Ia.8, 9, or any other cytotoxic antibody. Attempts to introduce a different genetic background into these immunization procedures was also without effect (Table V) and it should be noted that except for the BALB/c-dm 1 and drn e mutations--where there is an alteration or loss of D d + L d and L d molecules respectively, almost all attempts at immunization in mutants have failed to produce such an antibody (3). The MLR data (Table V) indicate that in addition to inducing histocompatibility, and serological alterations in IA subregion specificities, there is also the induction of surface molecules which stimulate the parental C57BL/6 strain. Furthermore, the degree of stimulation is similar to that achieved with differences arising of the whole 1-1-2 complex (21-23) , or more particularly, with known differences in the IA or K + IA regions (Table VI) . At this stage, it should be noted that the strongest MLR-stimulating determinants are coded for by the Lad-1 locus in the IA subregion and other Lad loci are found in K and D regions, in IJ, IC/E, and the non-H-2 linked Mls locus (23) . The finding that bm 12 stimulates C57BL/6 to respond equally well or better than B10.A(4R), a difference of the K + IA regions, provides strong evidence that the mutation has directly effected the Lad-1 locus itself to provide new Lad-l-stimulating determinants. At this time, the nature and number of these determinants is unknown as is their relationship to determinants involved in the CML phenomenon but this is currently under intensive study (K. Melief, personal communication). However, based on studies with the H-2K b mutants, it is likely that multiple specificities are involved (6) .
The bm TM mutation is of great importance in immunology--far beyond the formal description of another mutant. The initial studies reported herein, have clearly answered several important questions. Firstly, are serologically detected Ia specificities coded for by the same gene as the histocompatibility H-2IA gene or a closely associated H-gene? This question has remained unanswered although a clear association between the two was apparent. Both were products of the same subregion (IA) and no graft rejection occurred when there were no Ia incompatibilities; furthermore, anti-Ia sera could produce skin graft enhancement, and finally, anti-Ia antibodies were produced after graft rejection--compelling evidence for the close association, but not necessarily identity, of these two different moieties. The finding that the one mutation effected both graft rejection and serologically defined specificities indicates that the two are most likely to be present on the same molecule, and coded for by the same gene; although this may be an oversimplification and implies that T cells recognize the same specificities as antibody.
The second finding of importance is that bm 12 stimulates C57BL/6 in a MLR. This finding strongly suggests that the Ia determinants defined serologically, and the MLR-stimulating determinants, coded for by the Lad-1 locus are present on the same molecule, insofar that they are coded for by the same gene (Ia-l) . The studies therefore point to the identity of the Ia-1, H-2(IA), and Lad-1 genes. We should also question the relevance of the mutation in bm 12 to the definition of other I region products, particularly those detected serologically. We have not yet examined/jb but plan to do so. What of IE + and IC b products? These have not been defined with alloantisera in the mouse but we are currently investigating these specificities using both alloantisera and xenoantisera absorbed with the bm 12 mutant. These studies are of particular relevance as it has been suggested that a gene in the IA subregion (possibly Ia-1) also codes for one chain in the dimeric IC/IE molecules (24, 25) . With appropriate antisera and by using both serological and biochemical approaches, it may be possible to demonstrate whether the bm 12 mutation has also affected these subregions, either directly or indirectly. The bm TM mutant is therefore clearly of importance and should be of further help in determining the relationship of/r genes to Ia specificities, factors involved in T-B-cell collaboration, and to other phenomena whose effects map to the IA subregion. Summary The B6.C-H-2 b=12 mutant is described and evidence is presented for the mutational site occurring in the IA subregion. The mutant is of the gain and loss type as bm 12 ~ C57BL/6 grafts are rejected in 14-16 d. Mapping studies by the genecomplementation method using H-2 recombinant strains place the mutation in the K or IA regions of the H-2 complex and furthermore, the use of this test and the use of other H-2 mutants indicate that H-2K b is not the site of the mutation, making the IA region the most likely site. Serological analysis with a battery of H-2 b, Ia b, and other Ia sera, both by cytotoxicity, rosetting, and also by absorption analysis, indicated no alteration in H-2 specifieities, particularly in H-2.K33. By contrast, all of the Iab specificities coded for by the IA subregion (Ia.3, 8, 9 , 15, and possibly 20) are extensively altered and are either absent or greatly reduced in amount indicating an extensive alteration in the Ia-bearing molecule. The bm 12 mutant strongly stimulates the parental C57BL/6 strain in an mixed lymphocyte reaction (MLR), and the reciprocal also occurs, the degree of stimulation being similar to that obtained with K + IA differences originating in another H-2 haplotype and points to the mutation effecting the Lad-1 locus. The presence of an extensive histocompatibility change, a marked alteration in the serologically detected Ia specificities, and a strong MLR, all produced by the one mutation, provides strong evidence for the identity of the Ia-1, Lad-l, and H-2(IA) loci in the IA subregion. The bm 12 mutant should be of value in determining the relationship of Ia specificities, Ir genes, and other phenomena effected by the I region.
